BeiGene Ltd
For the period ended Jun 30, 2024. Filed Aug 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c)
The following table describes for the quarterly period covered by this report each trading arrangement for the purchase or sale of Company securities adopted, modified orterminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement,” or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Dr. Xiaobin Wu(President, Chief Operating Officer) | Adoption(May 13, 2024) | Rule 10b5-1 trading arrangement | Sale | September 5, 2025 | Restricted Stock Units (“RSU”) and stock options equaling to up to 218,240 American Depositary Shares (“ADSs”) less any shares sold pursuant to Dr. Wu’s prior 10b5-1 plan, which expired on May 12, 2024, but prior to this trading plan’s selling start date. |
| Julia Wang(Former Chief Financial Officer) | Adoption(May 22, 2024) | Rule 10b5-1 trading arrangement | Sale | August 29, 2025 | 78,727 ADSs plus an additional number of ADSs subject to RSUs equal to the net number of shares resulting from applicable RSU vestings after sell-to-cover for withholding tax. |
| Dr. Lai Wang(Global Head of R&D) | Adoption(June 13, 2024) | Rule 10b5-1 trading arrangement | Sale | September 12, 2025 | 20,000 ADSs |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.